京东健康全系AI产品将接入云鹊医APP 向基层医生免费开放

This article covers a new strategic partnership between JD Health and YunQue Yi, a grassroots-level primary care platform. All of JD Health's AI-powered medical products will be integrated into the YunQue Yi app and opened for free to all registered primary care clinicians across China, ultimately bringing higher-quality primary care services to general patients.

1. The core product available through this partnership is JD Zhiyi, an AI physician tool developed by JD Health. It has integrated over 50 million medical literature and guideline resources, plus more than 160,000 drug package inserts. As of the announcement of the partnership, it already serves over 1 million clinicians nationwide and has supported more than 20 million assisted clinical decision-making cases.

2. JD Zhiyi recently completed a major version upgrade, adding three new practical features: a deep thinking mode adapted for complex cases, a medical calculator covering more than 200 commonly used clinical tools, and a research assistant to support primary care clinicians in academic work. It has also integrated authoritative oncology guidelines from the Chinese Anti-Cancer Association and upgraded its algorithm performance.

3. After the partnership goes live, grassroots patients will gain access to more standardized chronic disease follow-up and health monitoring, as well as more convenient drug purchasing and delivery services, greatly improving access to medications in primary care regions.

This strategic partnership between JD Health and YunQue Yi creates new opportunities for pharmaceutical brand owners to enter grassroots-level markets, delivering multi-dimensional value across marketing, channels and consumer trends.

1. For brand marketing: Brand owners can leverage the nationwide primary care clinician network built through this partnership to run下沉式 digital academic promotion, directly reaching frontline primary care clinicians and effectively solving the long-standing problem of difficult market penetration for traditional academic promotion.

2. For channel development: JD Health already covers 1 million natural villages across China, with 87.1% of county-level regions eligible for same-day or next-day delivery, laying a solid foundation for online and offline channel下沉. Brand owners can quickly complete grassroots market channel布局 using this existing system.

3. For consumer trends: The number of chronic disease patients purchasing medication in grassroots markets has grown more than 113% over three years, marking the entry of the grassroots chronic disease market into a high-growth phase. Brand owners can capitalize on this trend and precisely match user demand through the AI-assisted diagnosis + chronic disease management chain to expand market share.

This partnership builds an entirely new grassroots pharmaceutical service system, bringing clear incremental opportunities for pharmaceutical sellers and providing direction for business development.

1. Market opportunity: Demand for chronic disease medication in grassroots markets is growing rapidly, with total users up more than 113% over three years. JD Health has already completed delivery coverage across 1 million Chinese villages, with 87.1% of county-level regions offering same-day or next-day delivery. The foundation for growth in the grassroots market is fully mature, making it a high-growth incremental market worthy of布局.

2. Business model: The "AI-assisted diagnosis + primary care clinician + pharmaceutical supply chain" integrated model created through this partnership gives sellers a complete end-to-end chain from grassroots user acquisition to final delivery, allowing sellers to reach massive下沉 market users via this framework.

3. Opportunity note: Sellers can leverage the new traffic opportunities opened by this partnership, integrate into the system to expand grassroots business, use AI to match user demand more accurately, reduce customer acquisition costs, and improve conversion efficiency.

The partnership between JD Health and YunQue Yi brings new commercial opportunities for pharmaceutical manufacturers and provides a reference direction for their digital transformation.

1. Commercial opportunities: Manufacturers can use the grassroots primary care clinician network built through this partnership to run digital academic promotion, deliver product information directly to frontline primary care clinicians nationwide, quickly expand sales channels in下沉 markets, and unlock new growth space.

2. Product development and design: Through the AI-assisted diagnosis and chronic disease management system, manufacturers can quickly collect clinical feedback and demand from grassroots settings, helping adjust R&D direction and optimize product design to better meet the needs of grassroots patients and clinicians.

3. Insights for digital transformation: The "AI + supply chain" terminal empowerment model adopted in this partnership offers a new approach for pharmaceutical manufacturers to connect to end users. Manufacturers can quickly complete digital channel布局 by leveraging mature third-party AI and supply chain capabilities, rather than building the entire system from scratch.

This partnership reflects new development trends in the grassroots medical service industry, clarifies core industry pain points, and provides a referenceable solution direction.

1. Industry development trends: AI empowerment for grassroots healthcare has entered the implementation phase, with AI medical capabilities now being opened for free to primary care clinicians and monetized through back-end services. AI healthcare has also evolved from general capabilities to scenario-specific empowerment, and the industry has begun pushing for standardized evaluation of AI medical capabilities.

2. Core customer pain points: Primary care clinicians generally lack the capacity to handle complex cases, face high learning barriers for advanced medical tools, and have limited research support; pharmaceutical companies struggle with low penetration of marketing in下沉 markets; and grassroots patients face poor access to medication.

3. Reference solution: Industry players can integrate AI technical capabilities with existing primary care clinician networks, attract both B-end and C-end users by opening AI tools for free, then monetize through linked services including supply chain, academic promotion and chronic disease management to build an integrated healthcare service model.

This partnership provides a mature reference model for operational collaboration between healthcare platforms and clarifies the future development direction for the industry.

1. Platform collaboration model: Different platforms can achieve win-win outcomes through complementary capabilities. In this case, JD Health contributed AI technology and pharmaceutical supply chain capabilities, while YunQue Yi contributed its nationwide primary care clinician network. The two sides jointly built an integrated service model for shared monetization, without needing to build out full end-to-end capabilities independently.

2. Insights for platform operation: Platforms can attract target users by opening high-value core AI functions for free, continuously improve user value through feature iteration and upgrades, and thereby boost user stickiness and activity. The three new features added in the recent JD Zhiyi upgrade have further enhanced its appeal to primary care clinicians, for example.

3. Profitability and risk note: Platforms can develop multiple revenue streams including chronic disease management, drug delivery, and pharmaceutical academic promotion based on their existing user base, while prioritizing compliance operations—compliance is the foundation for platforms providing grassroots medical services.

This partnership demonstrates the latest developments in the domestic AI healthcare industry's commercial落地, explores a replicable new business model, and carries high research value.

1. New industry trends: AI healthcare has gradually evolved from the early model of institutional paid licensing, and is now exploring a new path of free access for front-end users with monetization through back-end supply chain and commercial services. The technical architecture of AI healthcare has also upgraded from passive question-answering to evidence-based intelligent agent architecture that can independently complete long-chain clinical tasks, and the industry is shifting from capability building to standardized evaluation system construction.

2. New business model: This partnership explores an integrated "AI capability + primary care clinician network + pharmaceutical supply chain" business model: it acquires primary care clinician users through free AI-assisted diagnosis tools, then generates revenue through chronic disease management, drug delivery and下沉 market academic promotion for pharmaceutical companies, solving the long-standing problem of difficult commercial落地 and monetization for AI healthcare.

3. Promising new research directions include: outcome evaluation of AI empowerment for grassroots healthcare, construction of standardized evaluation systems for evidence-based medical AI, growth patterns of medical services in下沉 markets, and sustainable monetization models for AI healthcare.